List of Inlyta drug patents
Inlyta is owned by Pf Prism Cv.
Inlyta contains Axitinib.
Inlyta has a total of 4 drug patents out of which 0 drug patents have expired.
Inlyta was authorised for market use on 27 January, 2012.
Inlyta is available in tablet;oral dosage forms.
Inlyta can be used as axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma, in combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma.
The generics of Inlyta are possible to be released after 12 January, 2037.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6534524 | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Apr, 2025
(2 years from now) | |
| US8791140 | PF PRISM CV | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
Dec, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570202 | PF PRISM CV | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
Feb, 2035
(11 years from now) | |
| US10869924 | PF PRISM CV | PD-L1 antagonist combination treatments |
Jan, 2037
(13 years from now) | |
Drugs and Companies using AXITINIB ingredient
Market Authorisation Date: 27 January, 2012
Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma
Dosage: TABLET;ORAL
INLYTA family patents
18
United States
7
Japan
7
European Union
4
Spain
4
China
3
Portugal
3
Mexico
3
Taiwan, Province of China
3
Korea, Republic of
3
Canada
3
Slovenia
3
Poland
3
Australia
2
Singapore
2
Russia
2
Brazil
2
New Zealand
2
Hong Kong
2
Cyprus
2
Hungary
2
Israel
2
Denmark
1
Turkey
1
Malaysia
1
IB
1
Philippines
1
Argentina
1
EA
1
South Africa
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic